Roche launches Hemlibra for the treatment of people suffering from haemophilia A without factor VIII inhibitors.
Hemlibra is a bispecific medicine which is injected under the patient’s skin in order to develop required proteins, activate the natural coagulation cascade and to restore the blood clotting process for people affecting with haemophilia A.
This is a first-ever medicine to exhibit superior efficacy compared to factor VIII prophylaxis in an intra-patient comparison.
Haemophilia A is a severe disorder in which a person’s blood does not clot properly, leading to uncontrolled and often spontaneous bleeding.
This breakthrough therapy is specially designed to significantly reduce the frequency of bleeding episodes in adults and children affecting with haemophilia A.
Hemlibra helps to prevent or reduce the frequency of bleeding episodes in patients with haemophilia A who have developed inhibitors to Factor VIII.
It is a first-in-class bispecific factor IXa- and factor X-directed antibody - delivered by subcutaneous injection once a week.
Besides reducing the number of bleeding episodes in patients, it also improves physical functioning.
Hemlibra showcased a significant reduction in treating bleeds compared to no prophylaxis. There will be no thrombotic microangiopathy or thrombotic events in the treatment.
Hemlibra is the first medicine to show superior efficacy compared to factor VIII prophylaxis, the standard of care for people with haemophilia A without inhibitors.